Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome

Nur F. Önen, E. T. Overton, R. Presti, C. Blair, W. G. Powderly, K. Mondy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: To examine risk factors for sub-optimal CD4 recovery on suppressive highly active antiretroviral therapy (HAART) and assess long-term clinical and immunological outcomes. Methods: Retrospective analysis of 286 HIV-positive patients from a university clinic who initiated HAART with CD4 count <350 cells/μL between January 1996 and July 2006 and achieved ≥52 weeks of viral suppression (VS). Sub-optimal and optimal CD4 count recovery were defined by gains of <150 and ≥150 cells/μL during the first year of VS, respectively. Risk factors were analysed by multivariate logistic regression and markers of immune maturation and activation were evaluated prospectively for a sub-group of patients with prolonged (>5 years) VS. Results: One hundred and two (36%) patients had sub-optimal CD4 recovery. Male gender, lower pre-HAART viral load, HAART toxicity and use of opportunistic infection (OI) prophylaxis were independent risk factors on multivariate analysis (P < 0.05). Outcomes of duration of VS on HAART (4 years), new OI events (1%) and mortality (5%) were similar between groups. Markers of immune maturation and activation were higher among patients with sub-optimal CD4 recovery (P < 0.05). Conclusions: Among HIV-positive patients with long-term VS, sub-optimal CD4 recovery was common but morbidity and mortality remained low. In addition, persistent CD4 T-cell activation appeared to blunt long-term CD4 gains.

Original languageEnglish (US)
Pages (from-to)439-446
Number of pages8
JournalHIV Medicine
Volume10
Issue number7
DOIs
StatePublished - 2009

Fingerprint

Highly Active Antiretroviral Therapy
Opportunistic Infections
HIV
Mortality
CD4 Lymphocyte Count
Viral Load
Multivariate Analysis
Biomarkers
Morbidity
T-Lymphocytes

Keywords

  • Sub-optimal CD4 recovery
  • Suppressive HAART
  • T-cell activation

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. / Önen, Nur F.; Overton, E. T.; Presti, R.; Blair, C.; Powderly, W. G.; Mondy, K.

In: HIV Medicine, Vol. 10, No. 7, 2009, p. 439-446.

Research output: Contribution to journalArticle

Önen, Nur F. ; Overton, E. T. ; Presti, R. ; Blair, C. ; Powderly, W. G. ; Mondy, K. / Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome. In: HIV Medicine. 2009 ; Vol. 10, No. 7. pp. 439-446.
@article{9f7097b37c0e4d9ca44ff3a9cd721aa0,
title = "Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome",
abstract = "Objectives: To examine risk factors for sub-optimal CD4 recovery on suppressive highly active antiretroviral therapy (HAART) and assess long-term clinical and immunological outcomes. Methods: Retrospective analysis of 286 HIV-positive patients from a university clinic who initiated HAART with CD4 count <350 cells/μL between January 1996 and July 2006 and achieved ≥52 weeks of viral suppression (VS). Sub-optimal and optimal CD4 count recovery were defined by gains of <150 and ≥150 cells/μL during the first year of VS, respectively. Risk factors were analysed by multivariate logistic regression and markers of immune maturation and activation were evaluated prospectively for a sub-group of patients with prolonged (>5 years) VS. Results: One hundred and two (36{\%}) patients had sub-optimal CD4 recovery. Male gender, lower pre-HAART viral load, HAART toxicity and use of opportunistic infection (OI) prophylaxis were independent risk factors on multivariate analysis (P < 0.05). Outcomes of duration of VS on HAART (4 years), new OI events (1{\%}) and mortality (5{\%}) were similar between groups. Markers of immune maturation and activation were higher among patients with sub-optimal CD4 recovery (P < 0.05). Conclusions: Among HIV-positive patients with long-term VS, sub-optimal CD4 recovery was common but morbidity and mortality remained low. In addition, persistent CD4 T-cell activation appeared to blunt long-term CD4 gains.",
keywords = "Sub-optimal CD4 recovery, Suppressive HAART, T-cell activation",
author = "{\"O}nen, {Nur F.} and Overton, {E. T.} and R. Presti and C. Blair and Powderly, {W. G.} and K. Mondy",
year = "2009",
doi = "10.1111/j.1468-1293.2009.00711.x",
language = "English (US)",
volume = "10",
pages = "439--446",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome

AU - Önen, Nur F.

AU - Overton, E. T.

AU - Presti, R.

AU - Blair, C.

AU - Powderly, W. G.

AU - Mondy, K.

PY - 2009

Y1 - 2009

N2 - Objectives: To examine risk factors for sub-optimal CD4 recovery on suppressive highly active antiretroviral therapy (HAART) and assess long-term clinical and immunological outcomes. Methods: Retrospective analysis of 286 HIV-positive patients from a university clinic who initiated HAART with CD4 count <350 cells/μL between January 1996 and July 2006 and achieved ≥52 weeks of viral suppression (VS). Sub-optimal and optimal CD4 count recovery were defined by gains of <150 and ≥150 cells/μL during the first year of VS, respectively. Risk factors were analysed by multivariate logistic regression and markers of immune maturation and activation were evaluated prospectively for a sub-group of patients with prolonged (>5 years) VS. Results: One hundred and two (36%) patients had sub-optimal CD4 recovery. Male gender, lower pre-HAART viral load, HAART toxicity and use of opportunistic infection (OI) prophylaxis were independent risk factors on multivariate analysis (P < 0.05). Outcomes of duration of VS on HAART (4 years), new OI events (1%) and mortality (5%) were similar between groups. Markers of immune maturation and activation were higher among patients with sub-optimal CD4 recovery (P < 0.05). Conclusions: Among HIV-positive patients with long-term VS, sub-optimal CD4 recovery was common but morbidity and mortality remained low. In addition, persistent CD4 T-cell activation appeared to blunt long-term CD4 gains.

AB - Objectives: To examine risk factors for sub-optimal CD4 recovery on suppressive highly active antiretroviral therapy (HAART) and assess long-term clinical and immunological outcomes. Methods: Retrospective analysis of 286 HIV-positive patients from a university clinic who initiated HAART with CD4 count <350 cells/μL between January 1996 and July 2006 and achieved ≥52 weeks of viral suppression (VS). Sub-optimal and optimal CD4 count recovery were defined by gains of <150 and ≥150 cells/μL during the first year of VS, respectively. Risk factors were analysed by multivariate logistic regression and markers of immune maturation and activation were evaluated prospectively for a sub-group of patients with prolonged (>5 years) VS. Results: One hundred and two (36%) patients had sub-optimal CD4 recovery. Male gender, lower pre-HAART viral load, HAART toxicity and use of opportunistic infection (OI) prophylaxis were independent risk factors on multivariate analysis (P < 0.05). Outcomes of duration of VS on HAART (4 years), new OI events (1%) and mortality (5%) were similar between groups. Markers of immune maturation and activation were higher among patients with sub-optimal CD4 recovery (P < 0.05). Conclusions: Among HIV-positive patients with long-term VS, sub-optimal CD4 recovery was common but morbidity and mortality remained low. In addition, persistent CD4 T-cell activation appeared to blunt long-term CD4 gains.

KW - Sub-optimal CD4 recovery

KW - Suppressive HAART

KW - T-cell activation

UR - http://www.scopus.com/inward/record.url?scp=67650664983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650664983&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2009.00711.x

DO - 10.1111/j.1468-1293.2009.00711.x

M3 - Article

C2 - 19459993

AN - SCOPUS:67650664983

VL - 10

SP - 439

EP - 446

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 7

ER -